Viewing data from:

SURMONTIL

NDA

TRIMIPRAMINE MALEATE | N016792 | TEVA WOMENS HEALTH INC

3 strengths0 unique patents0 unique exclusivities

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

API Supply Chain1 active DMF4 inactive

1 active API supplier hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

LUNDBECK PHARMACEUTICALS ITALY SPATRIMIPRAMINE MALEATE

DMF 59001985

RHONE POULENC INCInactiveTRIMIPRAMINE MALEATE

DMF 40781981

PCASInactiveTRIMIPRAMINE MALEATE

DMF 65231986

TEVA PHARMACEUTICAL INDUSTRIES LTDInactiveTRIMIPRAMINE MALEATE

DMF 176652004

SANOFI CHIMIEInactiveTRIMIPRAMINE MALEATE

DMF 251062011

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

4 letters from Drugs@FDA

Source: Drugs@FDA application documents.

Products (3)

Sort:

#001 — EQ 25MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RLD

0 patents0 exclusivities▴

CAPSULE;ORAL | Approved: Approved Prior to Jan 1, 1982

No patent or exclusivity listings for this strength.

#002 — EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RLD

0 patents0 exclusivities▾

CAPSULE;ORAL | Approved: Approved Prior to Jan 1, 1982

#003 — EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RLD

0 patents0 exclusivities▾

CAPSULE;ORAL | Approved: Sep 15, 1982